Literature DB >> 31431244

The Use of Rapid Tranquilization in Aggressive Behavior.

Sophie Hirsch1, Tilman Steinert.   

Abstract

BACKGROUND: Psychomotor agitation and aggressiveness in the context of mental illnessare medical emergencies. In a survey of six German psychiatric hospitals, 1.7 to 5 aggressive attacks per patient-year were reported. If talking to the patient has no calming effect, intervention with drugs is required. In this article, we review the evidence on tranquilizing drugs and discuss clinically relevant ethical and practical questions, e.g., with respect to involuntary medication.
METHODS: This review is based on pertinent articles retrieved by a selective search in MEDLINE, supplemented by a reference search.
RESULTS: The evidence for the treatment of psychomotor agitation with antipsychotic drugs and benzodiazepines is relatively good. Randomized, controlled trials and a number of Cochrane reviews are available. These publications, however, contain data only on patients who were able to give informed consent. Their findings are often not applicable to real-life emergencies, e.g., when the patient is intoxicated with alcohol or suffers from a pre-existing disease. Haloperidol has a relatively weak effect on aggression when given alone and can also cause side effects such as early dyskinesia and epileptic seizures. It should, therefore, no longer be used as monotherapy. On the other hand, haloperidol combined with benzodiazepines or promethazine and monotherapy with lorazepam, olanzapine, ziprasidone, or aripiprazole intramuscular are effective options for the treatment of aggressive psychomotor agitation.
CONCLUSION: All of these drugs, if accepted by the patient, can also have an additional, beneficial placebo effect, with the patient calming down more rapidly than could be explained on pharmacological grounds alone. It is, therefore, important in emergencies (as at other times) for the patient to be involved in treatment decisions to the greatest possible extent.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31431244      PMCID: PMC6712906          DOI: 10.3238/arztebl.2019.0445

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN: 1866-0452            Impact factor:   5.594


  34 in total

1.  Comparison of intramuscular olanzapine, orally disintegrating olanzapine tablets, oral risperidone solution, and intramuscular haloperidol in the management of acute agitation in an acute care psychiatric ward in Taiwan.

Authors:  Wen-Yu Hsu; Si-Sheng Huang; Bo-Shyan Lee; Nan-Ying Chiu
Journal:  J Clin Psychopharmacol       Date:  2010-06       Impact factor: 3.153

2.  Characteristics of aggression in a German psychiatric hospital and predictors of patients at risk.

Authors:  R Ketelsen; C Zechert; M Driessen; M Schulz
Journal:  J Psychiatr Ment Health Nurs       Date:  2007-02       Impact factor: 2.952

3.  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

Authors:  Jeffrey A Lieberman; T Scott Stroup; Joseph P McEvoy; Marvin S Swartz; Robert A Rosenheck; Diana O Perkins; Richard S E Keefe; Sonia M Davis; Clarence E Davis; Barry D Lebowitz; Joanne Severe; John K Hsiao
Journal:  N Engl J Med       Date:  2005-09-19       Impact factor: 91.245

Review 4.  Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses.

Authors:  R B Belgamwar; M Fenton
Journal:  Cochrane Database Syst Rev       Date:  2005-04-18

5.  Case reports of postmarketing adverse event experiences with olanzapine intramuscular treatment in patients with agitation.

Authors:  Stephen R Marder; Sebastian Sorsaburu; Eduardo Dunayevich; Jamie L Karagianis; Ian C Dawe; Deborah M Falk; Mary Anne Dellva; Janice L Carlson; Patrizia A Cavazzoni; Robert W Baker
Journal:  J Clin Psychiatry       Date:  2010-02-09       Impact factor: 4.384

6.  Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety.

Authors:  Leslie Citrome
Journal:  J Clin Psychiatry       Date:  2007-12       Impact factor: 4.384

7.  Psychiatric emergencies in prehospital emergency medical systems: a prospective comparison of two urban settings.

Authors:  Frank-Gerald Pajonk; Patrik Schmitt; Andreas Biedler; Jens Christian Richter; Wolfgang Meyer; Thomas Luiz; Christian Madler
Journal:  Gen Hosp Psychiatry       Date:  2008 Jul-Aug       Impact factor: 3.238

8.  Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam.

Authors:  Glenn W Currier; James C-Y Chou; David Feifel; Cynthia A Bossie; Ibrahim Turkoz; Ramy A Mahmoud; Georges M Gharabawi
Journal:  J Clin Psychiatry       Date:  2004-03       Impact factor: 4.384

9.  Use of restraints and pharmacotherapy in academic psychiatric emergency services.

Authors:  Michael H Allen; Glenn W Currier
Journal:  Gen Hosp Psychiatry       Date:  2004 Jan-Feb       Impact factor: 3.238

10.  [Coercive measures: a comparison between six psychiatric departments].

Authors:  R Ketelsen; M Schulz; M Driessen
Journal:  Gesundheitswesen       Date:  2010-02-17
View more
  3 in total

1.  Therapeutic Drug Monitoring.

Authors:  Ramona Dolscheid-Pommerich; Birgit Stoffel-Wagner
Journal:  Dtsch Arztebl Int       Date:  2019-10-11       Impact factor: 5.594

2.  In Reply.

Authors:  Sophie Hirsch; Tilman Steinert
Journal:  Dtsch Arztebl Int       Date:  2019-10-11       Impact factor: 5.594

3.  Pharmacotherapy, drug-drug interactions and potentially inappropriate medication in depressive disorders.

Authors:  Jan Wolff; Pamela Reißner; Gudrun Hefner; Claus Normann; Klaus Kaier; Harald Binder; Christoph Hiemke; Sermin Toto; Katharina Domschke; Michael Marschollek; Ansgar Klimke
Journal:  PLoS One       Date:  2021-07-22       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.